Trastuzumab Therapy in Non-Small Cell Lung Cancer Patients
Status:
Terminated
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
This is a prospective study assessing efficacy of trastuzumab therapy in pretreated NSCLC
patients. Patients with locally advanced or metastatic NSCLC, HER2 FISH positive and/or with
HER2 gene mutation, pretreated with at least one previous chemotherapy line will be
considered eligible for the trial. After evaluation of inclusion and exclusion criteria, and
after signature of informed consensus form, all eligible patients will receive trastuzumab 6
mg/kg every 3 weeks (8 mg/kg loading dose) until disease progression, unacceptable toxicity
or patient refusal.